Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Citations to this article

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
Michael P. Pender, … , Alan Coulthard, Rajiv Khanna
Michael P. Pender, … , Alan Coulthard, Rajiv Khanna
Published November 15, 2018
Citation Information: JCI Insight. 2018;3(22):e124714. https://doi.org/10.1172/jci.insight.124714.
View: Text | PDF | Corrigendum
Clinical Research and Public Health Clinical trials Neuroscience Article has an altmetric score of 250

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

  • Text
  • PDF
Abstract

BACKGROUND. Increasing evidence indicates a role for EBV in the pathogenesis of multiple sclerosis (MS). EBV-infected autoreactive B cells might accumulate in the CNS because of defective cytotoxic CD8+ T cell immunity. We sought to determine the feasibility and safety of treating progressive MS patients with autologous EBV-specific T cell therapy. METHODS. An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro–expanded autologous EBV-specific T cells targeting EBV nuclear antigen 1, latent membrane protein 1 (LMP1), and LMP2A. Following adoptive immunotherapy, we monitored the patients for safety and clinical responses. RESULTS. Of the 13 recruited participants, 10 received the full course of T cell therapy. There were no serious adverse events. Seven patients showed improvement, with 6 experiencing both symptomatic and objective neurological improvement, together with a reduction in fatigue, improved quality of life, and, in 3 patients, reduced intrathecal IgG production. All 6 patients receiving T cells with strong EBV reactivity showed clinical improvement, whereas only 1 of the 4 patients receiving T cells with weak EBV reactivity showed improvement (P = 0.033, Fisher’s exact test). CONCLUSION. EBV-specific adoptive T cell therapy was well tolerated. Clinical improvement following treatment was associated with the potency of EBV-specific reactivity of the administered T cells. Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS. TRIAL REGISTRATION. Australian New Zealand Clinical Trials Registry, ACTRN12615000422527. FUNDING. MS Queensland, MS Research Australia, Perpetual Trustee Company Ltd., and donations from private individuals who wish to remain anonymous.

Authors

Michael P. Pender, Peter A. Csurhes, Corey Smith, Nanette L. Douglas, Michelle A. Neller, Katherine K. Matthews, Leone Beagley, Sweera Rehan, Pauline Crooks, Tracey J. Hopkins, Stefan Blum, Kerryn A. Green, Zara A. Ioannides, Andrew Swayne, Blake T. Aftab, Kaye D. Hooper, Scott R. Burrows, Kate M. Thompson, Alan Coulthard, Rajiv Khanna

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 Total
Citations: 6 10 15 11 18 10 5 75
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (75)

Title and authors Publication Year
Epstein-Barr virus promotes T cell dysregulation in a humanized mouse model of multiple sclerosis
Jessica R. Allanach, Naomi M Fettig, Blair K. Hardman, Ariel R. Rosen, Vina Fan, Cynthia Chung, Erin J. Goldberg, Zachary J. Morse, Iryna Shanina, Galina Vorobeychik, Lisa C Osborne, Marc S Horwitz
Science advances 2025
Multiple sclerosis and infection: history, EBV, and the search for mechanism
SoRelle ED, Luftig MA
Microbiology and Molecular Biology Reviews : MMBR 2025
Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective
Arimitsu NN, Witkowska A, Ohashi A, Miyabe C, Miyabe Y
Frontiers in Immunology 2025
Safety and efficacy of antigen-specific therapeutic approaches for multiple sclerosis: Systematic review
Öztürk HK, Slanař O, Michaličková D
PLOS One 2025
Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long SA, McNamara J, Nguyen H, Serti E, Sumida TS, Herold KC
Nature Communications 2025
Epstein-Barr virus and multiple sclerosis: lesson learned to develop better nonhuman primate models.
Nguyen HD, Kim D, Kim YH, Flemington E, Giovannoni G, Park CG, Kim WK
Experimental & molecular medicine 2025
Characterization of T cell receptor repertoire in penile cancer.
Zhang J, Wang Y, Huang Y, Tan X, Xu J, Yan Q, Tan J, Zhang Y, Zhang J, Ma Q, Zhu H, Ye J, Zhu Z, Lan W
Cancer Immunology, Immunotherapy 2024
Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS): A state-of-the-art review and implications for vaccine development.
Mohammadzamani M, Kazemzadeh K, Chand S, Thapa S, Ebrahimi N, Yazdan Panah M, Shaygannejad V, Mirmosayyeb O
2024
Global analysis of T-cell groups reveals immunological features and common antigen targets of digestive tract tumors
Li X, Zhang Y, Guo S, Wu Z, Wang H, Huang Y, Wang Y, Qiu M, Lang J, Xiao Y, Zhu Y, Jin G, Hu L, Kong X
Journal of Cancer Research and Clinical Oncology 2024
From progression to progress: The future of multiple sclerosis
Oh J, Giacomini PS, Yong VW, Costello F, Blanchette F, Freedman MS
Journal of Central Nervous System Disease 2024
Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis
Thomas OG, Haigh TA, Croom-Carter D, Leese A, Van Wijck Y, Douglas MR, Rickinson A, Brooks JM, Taylor GS
PLoS pathogens 2024
A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression
Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R
Frontiers in immunology 2024
Establishment of a protocol for rapidly expanding Epstein-Barr-virus-specific cytotoxic T cells with enhanced cytotoxicity.
Fang CH, Cheng YF, Lin SR, Lai WY, Liao LR, Chiu YL, Lee JM
BMC Cancer 2024
Central Nervous System Disorders with Auto-Antibodies in People Living with HIV
Stroffolini G, Atzori C, Imperiale D, Trunfio M, Di Perri G, Calcagno A
Microorganisms 2024
TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice
Zhang X, Chen Y, Wang S, Zhong L, Xiang Z, Zhang X, Zhang S, Zhou X, Zhang W, Zhou Y, Zhang Q, Liang J, Luo Y, Wang Y, Chen L, Ye X, Feng Q, Zeng MS, Liu Y, Zeng YX, Shao Y, Xu M
Emerging Microbes & Infections 2024
Autologous Epstein–Barr virus‐specific adoptive T‐cell therapy in a patient with lupus nephritis
Ranganathan D, Leibowitz S, John GT, Neller MA, Ambalathingal GR, Beagley L, Panikkar A, Best S, Raju J, Reddiex H, Ratanjee S, Ng MS, Smith C, Khanna R
Clinical & Translational Immunology 2024
Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond
Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E
HemaSphere 2023
Potential molecular mechanisms of chronic fatigue in long haul COVID and other viral diseases
Gottschalk CG, Peterson D, Armstrong J, Knox K, Roy A
Infectious agents and cancer 2023
Unstable EBV latency drives inflammation in multiple sclerosis patient derived spontaneous B cells
Soldan S, Su C, Monaco MC, Brown N, Clauze A, Andrada F, Feder A, Planet P, Kossenkov A, Schäffer D, Ohayon J, Auslander N, Jacobson S, Lieberman P
Research square 2023
Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old.
Clark F, Gil A, Thapa I, Aslan N, Ghersi D, Selin LK
Frontiers in immunology 2023
Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis.
Smith C, Khanna R
IBMS BoneKEy 2023
Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model
Reguraman N, Hassani A, Philip PS, Pich D, Hammerschmidt W, Khan G
Human vaccines 2023
Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers
Ortega-Hernandez OD, Martínez-Cáceres EM, Presas-Rodríguez S, Ramo-Tello C
International journal of molecular sciences 2023
Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis.
Magliozzi R, Howell OW, Calabrese M, Reynolds R
Nature reviews. Neurology 2023
Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review
Lambert N, El Moussaoui M, Baron F, Maquet P, Darcis G
Viruses 2023
Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice.
Dasari V, McNeil LK, Beckett K, Solomon M, Ambalathingal G, Thuy TL, Panikkar A, Smith C, Steinbuck MP, Jakubowski A, Seenappa LM, Palmer E, Zhang J, Haqq CM, DeMuth PC, Khanna R
Nature Communications 2023
EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
Monaco MCG, Soldan SS, Su C, Clauze A, Cooper JF, Patel RJ, Lu F, Hughes RJ, Messick TE, Andrada FC, Ohayon J, Lieberman PM, Jacobson S
Neurology: Neuroimmunology & Neuroinflammation 2023
Pathogenesis and therapeutic implications of EBV-associated epithelial cancers
Low YH, Loh CJ, Peh DY, Chu AJ, Han S, Toh HC
Frontiers in Oncology 2023
Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
Hartung HP, Cree BA, Barnett M, Meuth SG, Bar-Or A, Steinman L
Frontiers in immunology 2023
Regulatory T Cells in Multiple Sclerosis Diagnostics—What Do We Know So Far?
Arneth B
Journal of Personalized Medicine 2023
Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series
Gil A, Hoag GE, Salerno JP, Hornig M, Klimas N, Selin LK
2023
Prevention of MS Requires Intervention on the Causes of the Disease: Reconciling Genes, Epigenetics, and Epstein Barr Virus
P Kearns
Frontiers in neurology 2022
Therapeutic Advances in Multiple Sclerosis
Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS
Frontiers in neurology 2022
The enigmatic links between Epstein-Barr virus infection and multiple sclerosis
Tyler KL
Journal of Clinical Investigation 2022
The Potential for EBV Vaccines to Prevent Multiple Sclerosis
Maple PA, Ascherio A, Cohen JI, Cutter G, Giovannoni G, Shannon-Lowe C, Tanasescu R, Gran B
Frontiers in neurology 2022
Epstein–Barr virus and multiple sclerosis
Soldan SS, Lieberman PM
Nature reviews. Microbiology 2022
Altered Immune Response to the Epstein-Barr Virus as a Prerequisite for Multiple Sclerosis.
Läderach F, Münz C
Cells 2022
Epstein-Barr virus, interleukin-10 and multiple sclerosis: A ménage à trois
Schönrich G, Abdelaziz MO, Raftery MJ
Frontiers in immunology 2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T
CNS Drugs 2022
Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH, Zheng JH, Jia QY, Duan ZH, Yao HF, Yang J, Sun YW, Jiang SH, Liu DJ, Huo YM
Cellular oncology (Dordrecht) 2022
What do animal models tell us about the role of EBV in the pathogenesis of multiple sclerosis?
Hassani A, Khan G
Frontiers in immunology 2022
Comprehensive Analysis of Epstein-Barr Virus LMP2A-Specific CD8+ and CD4+ T Cell Responses Restricted to Each HLA Class I and II Allotype Within an Individual
Jo HA, Hyun SJ, Hyun YS, Lee YH, Kim SM, Baek IC, Sohn HJ, Kim TG
Immune Network 2022
Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells
CB Schroeter, N Huntemann, S Bock, C Nelke, D Kremer, K Pfeffer, SG Meuth, T Ruck
Frontiers in immunology 2021
The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis
C Veroni, F Aloisi
Frontiers in immunology 2021
Gender and the Sex Hormone Estradiol Affect Multiple Sclerosis Risk Gene Expression in Epstein-Barr Virus-Infected B Cells
JT Keane, A Afrasiabi, SD Schibeci, N Fewings, GP Parnell, S Swaminathan, DR Booth
Frontiers in immunology 2021
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
X Cui, CM Snapper
Frontiers in immunology 2021
Epstein Barr Virus Exploits Genetic Susceptibility to Increase Multiple Sclerosis Risk
F Läderach, C Münz
Microorganisms 2021
Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes
SS Soldan, C Su, RJ Lamontagne, N Grams, F Lu, Y Zhang, JD Gesualdi, DM Frase, LE Tolvinski, K Martin, TE Messick, JT Fingerut, E Koltsova, A Kossenkov, PM Lieberman, MA Luftig
PLoS pathogens 2021
Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis
UC Meier, RC Cipian, A Karimi, R Ramasamy, JM Middeldorp
Frontiers in immunology 2021
Do Epstein–Barr Virus Mutations and Natural Genome Sequence Variations Contribute to Disease?
P Farrell, R White
Biomolecules 2021
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients
E Naidus, J Bouquet, DY Oh, TJ Looney, H Yang, L Fong, NE Standifer, L Zhang
Cancer Immunology, Immunotherapy 2021
Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study
Y Cao, L Xie, F Shi, M Tang, Y Li, J Hu, L Zhao, L Zhao, X Yu, X Luo, W Liao, AM Bode
Signal Transduction and Targeted Therapy 2021
Mechanistic underpinning of an inside–out concept for autoimmunity in multiple sclerosis
BA t Hart, A Luchicchi, GJ Schenk, PK Stys, JJ Geurts
Annals of Clinical and Translational Neurology 2021
Endogenous Retroviruses in Nervous System Disorders
V Gröger, A Emmer, M Staege, H Cynis
Pharmaceuticals (Basel, Switzerland) 2021
Signaling pathways of EBV-induced oncogenesis
Y Luo, Y Liu, C Wang, R Gan
Cancer Cell International 2021
Epstein-Barr virus: Current questions and challenges
L Frappier
2021
Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1
JM Knerr, TN Kledal, MM Rosenkilde
Cancers 2021
Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy
ZA Ioannides, PA Csurhes, NL Douglas, G Mackenroth, A Swayne, KM Thompson, TJ Hopkins, KA Green, S Blum, KD Hooper, KH Wyssusek, A Coulthard, MP Pender
Frontiers in neurology 2021
Multiple sclerosis and drug discovery: A work of translation
BA t Hart, A Luchicchi, GJ Schenk, J Killestein, JJ Geurts
EBioMedicine 2021
Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis
A Hassani, N Reguraman, S Shehab, G Khan
Frontiers in immunology 2021
Epstein-Barr virus infection in the development of neurological disorders
SS Soldan, PM Lieberman
Drug discovery today. Disease models 2020
Vaccination against the Epstein–Barr virus
J Rühl, CS Leung, C Münz
Cellular and Molecular Life Sciences 2020
Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective
D Jakimovski, B Weinstock-Guttman, M Ramanathan, MG Dwyer, R Zivadinov
Human vaccines 2020
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
A Bar-Or, MP Pender, R Khanna, L Steinman, HP Hartung, T Maniar, E Croze, BT Aftab, G Giovannoni, MA Joshi
Trends in Molecular Medicine 2020
Pyoderma gangrenosum
E Maverakis, AV Marzano, ST Le, JP Callen, MC Brüggen, E Guenova, J Dissemond, K Shinkai, SM Langan
Nature Reviews Disease Primers 2020
Hypothesis: bipolar disorder is an Epstein–Barr virus‐driven chronic autoimmune disease – implications for immunotherapy
MP Pender
IBMS BoneKEy 2020
Cytomegalovirus and Epstein–Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development
PA Maple
Human vaccines 2020
Epstein-Barr Virus and Multiple Sclerosis
G Houen, NH Trier, JL Frederiksen
Frontiers in immunology 2020
Role of Viruses in the Pathogenesis of Multiple Sclerosis
RE Tarlinton, E Martynova, AA Rizvanov, S Khaiboullina, S Verma
Viruses 2020
Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges
Sabino Luzzi, Alice Giotta Lucifero, Ilaria Brambilla, Mariasole Magistrali, Mario Mosconi, Salvatore Savasta, Thomas Foiadelli
Acta bio-medica : Atenei Parmensis 2020
The ‘cognitive behavioural model’ of chronic fatigue syndrome: Critique of a flawed model
K Geraghty, L Jason, M Sunnquist, D Tuller, C Blease, C Adeniji
Health Psychology Open 2019
Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein–Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth
K Wojtak, A Perales-Puchalt, DB Weiner
Human vaccines 2019
Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism
B Serafini, B Rosicarelli, C Veroni, GA Mazzola, F Aloisi, RM Longnecker
Journal of virology 2019
Recent advances in understanding multiple sclerosis
PK Stys, S Tsutsui
F1000Research 2019
The promise of a prophylactic Epstein–Barr virus vaccine
H Balfour, D Schmeling, J Grimm-Geris
Pediatric Research 2019

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts

Picked up by 24 news outlets
Blogged by 6
Posted by 65 X users
On 5 Facebook pages
Reddited by 1
Highlighted by 1 platforms
189 readers on Mendeley
1 readers on CiteULike
See more details